Navigation Links
Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System
Date:8/8/2011

IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ Endovascular AAA System was performed at Edward Hines, Jr. VA Hospital in Chicago, IL. The procedure was performed by Ross Milner, M.D., F.A.C.S., Associate Professor and Chief of Vascular Surgery & Endovascular Therapy at Loyola University in Chicago, IL.

Dr. Milner commented, "We are excited to be the first hospital in the U.S. to bring the benefits of the new AFX system to a patient in our local community. The device builds on the compelling clinical evidence supporting Endologix's unique anatomical fixation technology with an enhanced, lower profile delivery system and new graft material. The 17Fr introducer sheath and integrated delivery system make it easy to use in a wide range of patient anatomies. The AFX system performed very well during the procedure; the delivery and deployment of the stent graft was quick and precise, and post-procedure imaging confirmed that the aneurysm was effectively sealed."

John McDermott, President and Chief Executive Officer of Endologix, commented, "We are pleased with the results from the initial implant and would like to thank Dr. Milner and his team for performing the procedure. We look forward to providing this exciting new endovascular device to physicians and patients in the U.S. in September."

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking StatementsExcept for historical information contained herein, this news release contains forward-looking statements relating to the planned launch of the AFX system, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the uncertainties related to the introduction and clinical acceptance of new products. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.COMPANY CONTACT:

INVESTOR CONTACTS:Endologix, Inc.

The Ruth GroupJohn McDermott, CEO

Nick Laudico (646) 536-7030(949) 595-7200

Zack Kubow (646) 536-7020www.endologix.com
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix to Present at Two Upcoming Conferences
2. Endologix Reports 22% Second Quarter 2011 Revenue Growth
3. Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products
4. Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011
5. Endologix Announces FDA Approval of AFX™ Endovascular AAA System
6. Endologix to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
7. Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized
8. Endologix to Present at the ROTH 23rd Annual OC Growth Stock Conference
9. Endologix Reports 41% Fourth Quarter 2010 Revenue Growth
10. Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
11. Endologix Announces Favorable Clinical Results for Nellix Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- The Board of Directors of Nordic Nanovector ... including the complete 2016 Annual Accounts with notes. The report ... website in the section Investor Relations/Reports and presentations/Annual Reports. ... For further ... Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... March 23, 2017  Transportation Insight, a multi-modal lead ... supply chain management firm with expertise serving clients in ... Rick Zaffarano was named a 2017 ... Chain by the only publication exclusively dedicated to covering ... chain. "Rick has brought to Transportation Insight ...
(Date:3/23/2017)... , March 23, 2017 ... Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria ... of the Primary Hyperoxaluria (Genito Urinary System And ... a rare condition characterized by recurrent kidney and ... a substance called oxalate. Symptoms include blood in ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study ... because it does not obey the rules Congress has directed the CBO to follow. ... the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly ... Delgado, June 9--24, 2017. This sacred and spiritual journey during the Summer ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... the year of enhancements, upgrading their training and leads programs. , In February, ... Reserved for elite sales agents, Performance Partners is designed to teach how to ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
Breaking Medicine News(10 mins):